Over the past decade, pharmaceutical and life sciences companies have had to navigate a challenging and rapidly changing environment, in which stakeholders such as shareholders, physicians, patients, payers and regulators are creating significant pressures for change. Despite steady demand for its products, the industry’s current business model is both economically unsustainable and operationally unsuited to the kind of quick action necessary to produce treatments demanded by global societies.
PricewaterhouseCoopers believes that the industry needs a bold new vision and leaders who have the willingness to embrace a fundamentally new approach to their business.
Pharmaceuticals and life sciences industry challenges
PricewaterhouseCoopers Pharma 2020 series Pharma 2020: The vision, the first in a series of papers, demonstrates how, to address these new demands, the industry will need to fundamentally change the way it operates. Companies will need to better understand and demonstrate the value of their products, lower their costs of distribution, collaborate with partners at home and abroad, and provide value-added services to their customers.
The second paper, Pharma 2020: Virtual R&D, provides a far-reaching perspective on the change drivers that will impact research and development productivity, creating new opportunities for companies to develop truly innovative products. The third paper, Pharma 2020: Marketing the future, discusses the key forces reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and patients, and the changes required to create a marketing and sales model that is fit for the 21st century. The fourth paper, Pharma 2020: Challenging business model, explains why Pharma's fully integrated business models may not be the best option for the pharma industry in 2020 and why more creative collaboration models may be more attractive. The paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.
How PricewaterhouseCoopers can help you
Whether you are an emerging company seeking venture capital to fund research or advice on a collaboration to commercialise a product, or an established company looking to improve or expand operations, you can count on our insight and experience to help you find the best approaches to achieving your financial, operational and strategic objectives.
PricewaterhouseCoopers has extensive experience working with proprietary and generic drug manufacturers, specialty drug makers, medical device and diagnostics suppliers, biotechnology companies, wholesalers, pharmacy benefit managers, contract research organisations, and industry associations. We have made a deep commitment to understanding the forces affecting our clients' operations and have aligned our practice with the market to ensure that our people are deeply knowledgeable about the relationships that suppliers have with providers, payers, regulators and patients.
More than 2,800 dedicated specialists in the PricewaterhouseCoopers’ global pharmaceutical and life sciences network are working with the top companies in the industry, using their distinctive point of view to deliver tailored strategic, operational and financial business solutions across the entire industry value chain.
